A global leader in influenza prevention recently announced a significant investment in a new Research and Development (R&D) facility located in Waltham, Mass.
Seqirus, a business of CSL Limited, confirmed on February 7, 2022, the new facility will support the company’s growing R&D portfolio, focusing on a self-amplifying messenger RNA (sa-mRNA) technology platform, the next generation of mRNA technology.
Read More
